NEW YORK — Clinical genomics informatics firm PierianDx said on Monday that it has closed a $27 million Series B financing round.
The round was led by ATW Partners and SJF Ventures, and included existing investors Health Catalyst Capital, Inova Health Systems, RTI International, and ARUP Laboratories.
St. Louis, Missouri-based PierianDx offers products and services for analyzing, interpreting, and reporting clinical next-generation sequencing data with a focus on cancer.Â
"Our new capital infusion will accelerate the commercial expansion of PierianDx's leading clinical genomics platform in the US and global markets throughout Europe, Asia, Australia, Latin America, and North America as we continue to work with leading sequencer, assay, and pharma partners," PierianDx CEO Michael Sanderson said in a statement.
PierianDx recently partnered with Illumina to develop cancer sequencing assays. It has also formed strategic alliances with ScienceVision, RTI, and Cancer Genetics.
PierianDx raised more than $3 million in early 2018 and closed a $9.25 million Series A in 2016.